Amneal Pharmaceuticals, Inc. (AMRX) Stock AnalysisAMRXStock AnalysisAmneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Amneal Pharmaceuticals is a good buy right now due to its strong financial performance and positive market sentiment. The current price is $17.54, and the company recently reported a Q2 2026 non-GAAP EPS of $0.30, exceeding expectations by $0.07. Additionally, the forward P/E ratio is notably low at 6.30, suggesting that the stock is undervalued relative to its earnings potential. The main risk is the debt to equity ratio, which stands at an extremely high 8261.93%, indicating significant leverage that could impact financial stability.